Onconova Q1 net loss $5.8M; rigosertib achieves complete responses in RDEB-SCC

Traws Pharma, Inc.

2023-Q1 EPS reported -$0.28 revenue$56,000

Cash $34.2M as of March 31, 2023; expects runway into Q1 2024.
Net loss $5.8M ($0.28/sh) vs $4.1M ($0.20/sh) in Q1 2022; R&D expenses doubled to $4.1M.
First patient dosed in Phase 1/2a trial of narazaciclib plus letrozole in LGEEC; preliminary data expected Q4 2023.
Both evaluable patients in rigosertib RDEB-SCC trial achieved complete cutaneous remissions; FDA Type B meeting requested.
Entered collaboration with Pangea Biomed to identify biomarkers for rigosertib response.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Traws Pharma, Inc. reported the three months ended March 31, 2023 results: net income $5.8 million, EPS $0.28 per share.

Period: the three months ended March 31, 2023
Net income: $5.8 million
EPS: $0.28 per share
Result: reported results

Exact text from the filing

Net loss for the first quarter of 2023 was $5.8 million, or $0.28 per share on 20.9 million weighted shares outstanding, compared with a net loss of $4.1 million, or $0.20 per share for the first quarter of 2022 on 20.9 million weighted shares outstanding.

View on SEC.gov

Browse all earnings releases →

Traws Pharma, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-060943

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.